dinutuximab

{
  "id": "MLC-T-ONC-002480",
  "term": "dinutuximab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (IL-2), and 13-cis-retinoic acid to treat children with high-risk neuroblastoma. It is used in patients whose disease has gotten better with other anticancer treatment. Dinutuximab binds to a substance called GD2, which is found on some types of cancer cells. Dinutuximab may block GD2 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called Ch14.18, MOAB Ch14.18, monoclonal antibody Ch14.18, and Unituxin.",
    "A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells. GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung."
  ],
  "abbreviation": "MOAB Ch14.18",
  "synonyms": [
    "Ch14.18",
    "MOAB Ch14.18",
    "monoclonal antibody Ch14.18",
    "Unituxin",
    "Ch 14.18UTC",
    "dinutuximab beta"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/dinutuximab/"
}